IL276311B2 - Methyllactam ring compound and its pharmaceutical use - Google Patents

Methyllactam ring compound and its pharmaceutical use

Info

Publication number
IL276311B2
IL276311B2 IL276311A IL27631120A IL276311B2 IL 276311 B2 IL276311 B2 IL 276311B2 IL 276311 A IL276311 A IL 276311A IL 27631120 A IL27631120 A IL 27631120A IL 276311 B2 IL276311 B2 IL 276311B2
Authority
IL
Israel
Prior art keywords
methyllactam
pharmaceutical use
ring compound
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
IL276311A
Other languages
English (en)
Hebrew (he)
Other versions
IL276311A (en
IL276311B1 (en
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of IL276311A publication Critical patent/IL276311A/en
Publication of IL276311B1 publication Critical patent/IL276311B1/en
Publication of IL276311B2 publication Critical patent/IL276311B2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/41551,2-Diazoles non condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL276311A 2018-03-01 2019-02-28 Methyllactam ring compound and its pharmaceutical use IL276311B2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018036307 2018-03-01
PCT/JP2019/007799 WO2019168096A1 (ja) 2018-03-01 2019-02-28 メチルラクタム環化合物及びその医薬用途

Publications (3)

Publication Number Publication Date
IL276311A IL276311A (en) 2020-09-30
IL276311B1 IL276311B1 (en) 2023-06-01
IL276311B2 true IL276311B2 (en) 2023-10-01

Family

ID=67806229

Family Applications (1)

Application Number Title Priority Date Filing Date
IL276311A IL276311B2 (en) 2018-03-01 2019-02-28 Methyllactam ring compound and its pharmaceutical use

Country Status (21)

Country Link
US (3) US11014910B2 (https=)
EP (1) EP3760624A4 (https=)
JP (3) JP7206132B2 (https=)
KR (1) KR102795351B1 (https=)
CN (1) CN111757877B (https=)
AR (1) AR114418A1 (https=)
AU (1) AU2019227770B2 (https=)
BR (1) BR112020016788A2 (https=)
CA (1) CA3087859A1 (https=)
CL (1) CL2020002199A1 (https=)
IL (1) IL276311B2 (https=)
MA (1) MA52427A (https=)
MX (1) MX2020009070A (https=)
MY (1) MY205197A (https=)
PE (1) PE20210123A1 (https=)
PH (1) PH12020551340A1 (https=)
SA (1) SA520420037B1 (https=)
SG (1) SG11202007120UA (https=)
TW (1) TWI805699B (https=)
WO (1) WO2019168096A1 (https=)
ZA (1) ZA202004600B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
EP3778593A4 (en) 2018-04-04 2021-12-22 Japan Tobacco Inc. HETEROARYL-SUBSTITUTED PYRAZOLE COMPOUND AND ITS MEDICAL USE
JP7760370B2 (ja) * 2019-09-04 2025-10-27 日本たばこ産業株式会社 慢性腎臓病の治療又は予防方法
US20230119894A1 (en) * 2019-09-04 2023-04-20 Japan Tobacco Inc. Therapeutic or prophylactic method for diabetes using combination medicine
CA3175131A1 (en) 2020-03-19 2021-09-23 Chihiro Okuma Treatment or prevention method for chronic heart failure

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3657282A (en) * 1969-01-23 1972-04-18 Merck & Co Inc Carboxyepoxyethyl-1-phosphonic acid and derivatives
FR2665898B1 (fr) 1990-08-20 1994-03-11 Sanofi Derives d'amido-3 pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
JPH04247081A (ja) 1991-02-01 1992-09-03 Takeda Chem Ind Ltd 5員複素環酸アミド類
FR2692575B1 (fr) 1992-06-23 1995-06-30 Sanofi Elf Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant.
US7622471B2 (en) 2003-02-07 2009-11-24 Daiichi Pharmaceutical Co., Ltd. Pyrazole derivatives having a pyridazine and pyridine functionality
AU2004200420A1 (en) 2003-03-11 2004-09-30 Astellas Pharma Inc. Inhibitor of cyclooxygenase
JP2006182648A (ja) 2003-04-08 2006-07-13 Dai Ichi Seiyaku Co Ltd 7員複素環誘導体
WO2004110351A2 (en) 2003-05-14 2004-12-23 Anadys Pharmaceuticals, Inc. Heterocyclic compounds for treating hepatitis c virus
TW200526588A (en) 2003-11-17 2005-08-16 Smithkline Beecham Corp Chemical compounds
TW200526641A (en) 2003-12-26 2005-08-16 Daiichi Seiyaku Co Amidopyrazole derivatives
CN1980665A (zh) 2004-07-07 2007-06-13 默克公司 吡唑酰胺衍生物,包含这些化合物的组合物和使用方法
AU2005305675B2 (en) 2004-11-16 2012-12-13 Jazz Pharmaceuticals Operations Uk Limited New use for cannabinoid
JP2008007405A (ja) 2004-12-07 2008-01-17 Takeda Chem Ind Ltd カルボキサミド誘導体
JP4137956B2 (ja) * 2005-06-08 2008-08-20 日本たばこ産業株式会社 複素環化合物
KR100970294B1 (ko) 2005-06-08 2010-07-15 니뽄 다바코 산교 가부시키가이샤 복소환 화합물
ZA200800142B (en) * 2005-06-08 2009-05-27 Japan Tobacco Inc Heterocyclic compound
WO2007034279A2 (en) * 2005-09-19 2007-03-29 Pfizer Products Inc. C3a antagonists and pharmaceutical compositions thereof
WO2007098826A2 (en) 2006-01-18 2007-09-07 Siena Biotech S.P.A. Modulators of alpha7 nicotinic acetylcholine receptors and therapeutic uses thereof
EP2026798A1 (en) * 2006-04-27 2009-02-25 Solvay Pharmaceuticals GmbH Pharmaceutical compositions comprising cbx cannabinoid receptor modulators and potassium channel modulators
US20080027014A1 (en) 2006-07-28 2008-01-31 Tanabe Seiyaku Co., Ltd. Novel SGLT inhibitors
KR101450356B1 (ko) 2006-11-24 2014-10-15 에이씨 이뮨 에스.에이. 알츠하이머와 같은 아밀로이드 또는 아밀로이드-유사 단백질과 관련된 질환의 치료를 위한 n-(메틸)-1h-피라졸-3-아민, n-(메틸)-피리딘-2-아민 및 n-(메틸)-티아졸-2-아민 유도체
EP2121619A2 (en) 2006-11-24 2009-11-25 AC Immune S.A. Compounds for the treatment of diseases associated with amyloid or amyloid-like proteins
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
JP5583003B2 (ja) * 2007-04-02 2014-09-03 セラコス・インコーポレイテッド ベンジルグルコシド誘導体およびその用途
WO2009091813A1 (en) 2008-01-14 2009-07-23 Wyeth Compounds useful as alpha7 nicotinic acetylcholine receptor agonists
EP2349484A2 (en) 2008-07-15 2011-08-03 Novartis AG Heteroaryl derivatives as dgat1 inhibitors
CN102918034B (zh) 2010-03-30 2015-06-03 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
AR087701A1 (es) * 2011-08-31 2014-04-09 Japan Tobacco Inc Derivados de pirazol con actividad inhibidora de sglt1
KR102727059B1 (ko) * 2015-02-16 2024-11-05 더 유니버서티 어브 퀸슬랜드 설포닐우레아와 관련 화합물 및 그 용도
CN109071454B (zh) * 2016-02-16 2023-02-17 昆士兰大学 磺酰脲和相关化合物及其用途
TWI805699B (zh) * 2018-03-01 2023-06-21 日商日本煙草產業股份有限公司 甲基內醯胺環化合物及其用途
EP3778593A4 (en) 2018-04-04 2021-12-22 Japan Tobacco Inc. HETEROARYL-SUBSTITUTED PYRAZOLE COMPOUND AND ITS MEDICAL USE

Also Published As

Publication number Publication date
CL2020002199A1 (es) 2020-12-18
JP2023026566A (ja) 2023-02-24
MA52427A (fr) 2021-01-06
SA520420037B1 (ar) 2024-07-28
TWI805699B (zh) 2023-06-21
CN111757877A (zh) 2020-10-09
EP3760624A4 (en) 2021-11-03
PH12020551340A1 (en) 2021-05-31
US20190352284A1 (en) 2019-11-21
WO2019168096A1 (ja) 2019-09-06
MY205197A (en) 2024-10-07
US11014910B2 (en) 2021-05-25
CA3087859A1 (en) 2019-09-06
AU2019227770A1 (en) 2020-07-09
RU2020131756A (ru) 2022-03-28
TW202000660A (zh) 2020-01-01
BR112020016788A2 (pt) 2021-01-12
AR114418A1 (es) 2020-09-02
ZA202004600B (en) 2022-03-30
JP2019151627A (ja) 2019-09-12
IL276311A (en) 2020-09-30
JP2025026615A (ja) 2025-02-21
MX2020009070A (es) 2020-10-08
KR102795351B1 (ko) 2025-04-16
IL276311B1 (en) 2023-06-01
US20240174646A1 (en) 2024-05-30
EP3760624A1 (en) 2021-01-06
CN111757877B (zh) 2023-10-27
JP7206132B2 (ja) 2023-01-17
SG11202007120UA (en) 2020-08-28
KR20200128033A (ko) 2020-11-11
PE20210123A1 (es) 2021-01-19
US20220064148A1 (en) 2022-03-03
AU2019227770B2 (en) 2023-10-05

Similar Documents

Publication Publication Date Title
IL276311B1 (en) Methyllactam ring compound and its pharmaceutical use
SA521422143B1 (ar) 15-pgdh مثبط
ZA202206923B (en) New methylquinazolinone derivatives
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
EP4541422A3 (en) Quinoline derivatives as alpha4beta7 integrin inhibitors
FI3256218T3 (fi) Kdm1a-estäjät sairauksien hoidossa
IL314009B2 (en) Parp1 inhibitors and their uses
AU2020288567A8 (en) Pyrrolopyrimidine compound and use thereof
PH12019500849A1 (en) Naphthyridinone derivatives and their use inthe treatment of arrhythmia
PH12021552513A1 (en) Pyrrole compounds
AU2019375825A8 (en) Macrocyclic tyrosine kinase inhibitor and uses thereof
IL276194B2 (en) Pharmaceutical compounds or preparations containing them for use in the treatment of pain
EP4599892A3 (en) Boronic acid derivatives and therapeutic uses thereof
JP2019151627A5 (https=)
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
WO2019207257A8 (fr) Composes a activite inhibitrice de la polymerisation de la tubuline et aux proprietes immunomodulatrices
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
HK1254636A1 (zh) 作为可溶性鸟苷酸环化酶激活剂的茚满衍生物及其用途
MX2022006104A (es) Composicion farmaceutica oral que comprende compuesto de carbamato y metodo de preparacion para la misma.
MY194941A (en) C-glycoside derivatives having fused phenyl ring or pharmaceutically acceptable salts thereof, method for preparing the same and pharmaceutical composition comprising the same
WO2020068657A8 (en) 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof
GEAP202516217A (en) Compounds and compositions as sppl2a inhibitors
MX2022004213A (es) Derivados de 2-azaspiro[3.4]octano como agonistas de m4.
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
MY160963A (en) Sustained-release therapeutic agent for hypertension and renal dysfunction